Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
Bao Hoang(GlaxoSmithKline (United States)), Alan Lichtenstein(University of California, Los Angeles)
Cited by 120
Related Papers
Defensins: Antimicrobial and Cytotoxic Peptides of Mammalian Cells
|Annual Review of Immunology|1993|991
AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression
|Journal of Biological Chemistry|2004|329